BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Thomas DL. Global control of hepatitis C: where challenge meets opportunity. Nat Med 2013;19:850-8. [PMID: 23836235 DOI: 10.1038/nm.3184] [Cited by in Crossref: 215] [Cited by in F6Publishing: 225] [Article Influence: 23.9] [Reference Citation Analysis]
Number Citing Articles
1 Keikha M, Kamali H, Ghazvini K, Karbalaei M. Antimicrobial peptides: natural or synthetic defense peptides against HBV and HCV infections. VirusDis 2022. [DOI: 10.1007/s13337-022-00790-y] [Reference Citation Analysis]
2 Tsai WL, Cheng JS, Liu PF, Chang TH, Sun WC, Chen WC, Shu CW. Sofosbuvir induces gene expression for promoting cell proliferation and migration of hepatocellular carcinoma cells. Aging (Albany NY) 2022;14. [PMID: 35833210 DOI: 10.18632/aging.204170] [Reference Citation Analysis]
3 Sharma A, Virmani T, Sharma A, Chhabra V, Kumar G, Pathak K, Alhalmi A. Potential Effect of DPP-4 Inhibitors Towards Hepatic Diseases and Associated Glucose Intolerance. Diabetes Metab Syndr Obes 2022;15:1845-64. [PMID: 35733643 DOI: 10.2147/DMSO.S369712] [Reference Citation Analysis]
4 Gupta J, Irfan M, Ramgir N, Muthe KP, Debnath AK, Ansari S, Gandhi J, Ranjith-kumar CT, Surjit M. Antiviral Activity of Zinc Oxide Nanoparticles and Tetrapods Against the Hepatitis E and Hepatitis C Viruses. Front Microbiol 2022;13:881595. [DOI: 10.3389/fmicb.2022.881595] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Liu Y, Teng L, Yin B, Meng H, Yin X, Huan S, Song G, Zhang XB. Chemical Design of Activatable Photoacoustic Probes for Precise Biomedical Applications. Chem Rev 2022. [PMID: 35234464 DOI: 10.1021/acs.chemrev.1c00875] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 13.0] [Reference Citation Analysis]
6 Kaya M, Nakamura K, Sugiyama K, Kinae A, Yamaguchi H, Ukita H, Odagiri K, Ujiie C, Kato J, Kageyama F, Nagura M, Matsushita K, Sugiue K, Ishida H, Endo S, Suzuki T. Retrospective multicentre study on the effectiveness of first-line direct-acting antivirals against hepatitis C virus genotype-1. J Clin Pharm Ther 2022. [PMID: 35229326 DOI: 10.1111/jcpt.13624] [Reference Citation Analysis]
7 Deng X, Wu Y, Xu H, Yan J, Liu H, Zhang B. Recent research progress in galactose-based fluorescent probes for detection of biomarkers of liver diseases. Chem Commun 2022. [DOI: 10.1039/d2cc04180d] [Reference Citation Analysis]
8 Song X, Gao X, Wang Y, Raja R, Zhang Y, Yang S, Li M, Yao Z, Wei L. HCV Core Protein Induces Chemokine CCL2 and CXCL10 Expression Through NF-κB Signaling Pathway in Macrophages. Front Immunol 2021;12:654998. [PMID: 34531848 DOI: 10.3389/fimmu.2021.654998] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
9 Oraby AK, Gardner CL, Needle RF, Kofahi HM, Everard KR, Taylor NGA, Rutihinda SG, Barry JP, Hirasawa K, Georghiou PE, Russell RS. A Novel Small Molecule Inhibits Hepatitis C Virus Propagation in Cell Culture. Microbiol Spectr 2021;9:e0043921. [PMID: 34319169 DOI: 10.1128/Spectrum.00439-21] [Reference Citation Analysis]
10 Yamashita Y, Joshita S, Sugiura A, Yamazaki T, Kobayashi H, Wakabayashi SI, Yamada Y, Shibata S, Kunimoto H, Iwadare T, Matsumura M, Miyabayashi C, Okumura T, Ozawa S, Nozawa Y, Kobayashi N, Komatsu M, Fujimori N, Saito H, Umemura T. aMAP score prediction of hepatocellular carcinoma occurrence and incidence-free rate after a sustained virologic response in chronic hepatitis C. Hepatol Res 2021. [PMID: 34216422 DOI: 10.1111/hepr.13689] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
11 Avula K, Singh B, Kumar PV, Syed GH. Role of Lipid Transfer Proteins (LTPs) in the Viral Life Cycle. Front Microbiol 2021;12:673509. [PMID: 34248884 DOI: 10.3389/fmicb.2021.673509] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
12 Wang GP, Schnell GL, Kort JJ, Sidhu GS, Schuster L, Tripathi RL, Larsen L, Michael LC, Bergquist K, Magee A, Patel CB, Whitlock JA, Tamashiro R, Peter JA, Fried MW, Nelson DR. Linkage of resistance-associated substitutions in GT1 sofosbuvir + NS5A inhibitor failures treated with glecaprevir/pibrentasvir. J Hepatol 2021:S0168-8278(21)00339-1. [PMID: 34023351 DOI: 10.1016/j.jhep.2021.04.057] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Aydin Y, Koksal AR, Reddy V, Lin D, Osman H, Heidari Z, Rhadhi SM, Wimley WC, Parsi MA, Dash S. Extracellular Vesicle Release Promotes Viral Replication during Persistent HCV Infection. Cells 2021;10:984. [PMID: 33922397 DOI: 10.3390/cells10050984] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
14 Cowton VM, Owsianka AM, Fadda V, Ortega-Prieto AM, Cole SJ, Potter JA, Skelton JK, Jeffrey N, Di Lorenzo C, Dorner M, Taylor GL, Patel AH. Development of a structural epitope mimic: an idiotypic approach to HCV vaccine design. NPJ Vaccines 2021;6:7. [PMID: 33420102 DOI: 10.1038/s41541-020-00269-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
15 Kehr J. Bibliographie. Spectres de la tuberculose 2021. [DOI: 10.4000/books.pur.147950] [Reference Citation Analysis]
16 Owusu DO, Phillips R, Owusu M, Sarfo FS, Frempong M. Increased levels of circulating IL-10 in persons recovered from hepatitis C virus (HCV) infection compared with persons with active HCV infection. BMC Res Notes 2020;13:472. [PMID: 33028385 DOI: 10.1186/s13104-020-05313-w] [Reference Citation Analysis]
17 Alian SM, Wahba MO, Gomaa AF, Khalil SS. The efficacy and safety of direct-acting antiviral drugs in the management of hepatitis C virus-related arthritis. Egypt Rheumatol Rehabil 2020;47. [DOI: 10.1186/s43166-020-00021-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
18 Lian Z, Li C, Frimpong JA. Correlates of subjective hepatitis C knowledge among clinical staff in US drug treatment programs. J Public Health (Berl ) 2020;28:401-409. [DOI: 10.1007/s10389-019-01032-0] [Reference Citation Analysis]
19 Wong WCW, Yang NS, Li J, Li H, Wan EYF, Fitzpatrick T, Xiong Y, Seto WK, Chan P, Liu R, Tang W, Tucker JD. Crowdsourcing to promote hepatitis C testing and linkage-to-care in China: a randomized controlled trial protocol. BMC Public Health. 2020;20:1048. [PMID: 32615951 DOI: 10.1186/s12889-020-09152-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
20 Aziz H, Fatima S, Faheem M. Indeterminate Prediction of Hepatitis C Virus Genotype by Commercial Real-Time Polymerase Chain Reaction Assay Resolving by Sequencing to Avoid the Consequence of Inaccurate Typing. Viral Immunol 2020;33:507-13. [PMID: 32429831 DOI: 10.1089/vim.2019.0162] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 Dash S, Aydin Y, Widmer KE, Nayak L. Hepatocellular Carcinoma Mechanisms Associated with Chronic HCV Infection and the Impact of Direct-Acting Antiviral Treatment. J Hepatocell Carcinoma 2020;7:45-76. [PMID: 32346535 DOI: 10.2147/JHC.S221187] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 19.0] [Reference Citation Analysis]
22 Chen P, Zheng Y, Cai Y, Zou P, Li N, Peng C, Gao H, Liu J, Chen Y, Tong Z, Li L. Prevalence of Hepatitis C Virus Infection in a Surgical Population of Southeast China: A Large-Scale Multicenter Study. Can J Gastroenterol Hepatol 2020;2020:8219536. [PMID: 32377514 DOI: 10.1155/2020/8219536] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
23 Badawi R, Alboraie M, Abd-Elsalam S, Abourahma MZ, Ramadan HK, Ahmed OA, Fouad MHA, Soliman S, Mohareb DA, Haydara T, Alnabawy SM, El Kassas M. Serum Alpha-fetoprotein Levels and Response to Direct Antiviral Therapy in Patients with Chronic Hepatitis C: Real-world Results from 1716 Patients in Egypt. Endocr Metab Immune Disord Drug Targets 2019;19:1005-11. [PMID: 30727931 DOI: 10.2174/1871530319666190204154830] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
24 Boon D, Bruce V, Patel EU, Quinn J, Srikrishnan AK, Shanmugam S, Iqbal S, Balakrishnan P, Sievers M, Kirk GD, Thomas DL, Quinn TC, Cox AL, Page KA, Solomon SS, Mehta SH, Laeyendecker O. Antibody avidity-based approach to estimate population-level incidence of hepatitis C. J Hepatol 2020;73:294-302. [PMID: 32240715 DOI: 10.1016/j.jhep.2020.03.028] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
25 Ward JW, Hinman AR, Alter HJ. Time for the Elimination of Hepatitis C Virus as a Global Health Threat. The Liver 2020. [DOI: 10.1002/9781119436812.ch70] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Gupta E, Choudhary MC, Upadhyay N, Singh G, Nayak SL, Kumar M, Sarin SK. Lower Rates Of Naturally Occurring Resistance-Associated Substitutions (RASs) In Hepatitis C Virus (HCV)-Infected Chronic Kidney Disease (CKD) Patients Than In HCV-Infected Patients With Only Liver Disease. Infect Drug Resist 2019;12:3635-40. [PMID: 31819546 DOI: 10.2147/IDR.S220335] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
27 Liu Y, Teng L, Xu C, Liu HW, Xu S, Guo H, Yuan L, Zhang XB. A "Double-Locked" and enzyme-activated molecular probe for accurate bioimaging and hepatopathy differentiation. Chem Sci 2019;10:10931-6. [PMID: 32190249 DOI: 10.1039/c9sc03628h] [Cited by in Crossref: 45] [Cited by in F6Publishing: 47] [Article Influence: 15.0] [Reference Citation Analysis]
28 Aydin Y, Kurt R, Song K, Lin D, Osman H, Youngquist B, Scott JW, Shores NJ, Thevenot P, Cohen A, Dash S. Hepatic Stress Response in HCV Infection Promotes STAT3-Mediated Inhibition of HNF4A-miR-122 Feedback Loop in Liver Fibrosis and Cancer Progression. Cancers (Basel) 2019;11:E1407. [PMID: 31547152 DOI: 10.3390/cancers11101407] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
29 Lu G, Ou J, Zhao J, Li S. Presence of a Novel Subtype of Bovine Hepacivirus in China and Expanded Classification of Bovine Hepacivirus Strains Worldwide into 7 Subtypes. Viruses 2019;11:E843. [PMID: 31514278 DOI: 10.3390/v11090843] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
30 Dash S, Aydin Y, Wu T. Integrated stress response in hepatitis C promotes Nrf2-related chaperone-mediated autophagy: A novel mechanism for host-microbe survival and HCC development in liver cirrhosis. Semin Cell Dev Biol 2020;101:20-35. [PMID: 31386899 DOI: 10.1016/j.semcdb.2019.07.015] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
31 Huang J, Xu R, Wang M, Liao Q, Huang K, Shan Z, You Q, Li C, Rong X, Fu Y. Association of HLA-DQB1*03:01 and DRB1*11:01 with spontaneous clearance of hepatitis C virus in Chinese Li ethnicity, an ethnic group genetically distinct from Chinese Han ethnicity and infected with unique HCV subtype. J Med Virol 2019;91:1830-6. [PMID: 31254396 DOI: 10.1002/jmv.25531] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
32 Lioznov DA, Dunaeva NV, Chung NH, Gorchakova OV, Antonova TV. Chronic hepatitis C: modern condition of the problem. Nefrologiâ (St -Peterbg ) 2019;23:36-46. [DOI: 10.24884/1561-6274-2019-23-4-36-46] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
33 Holmstrom ED, Liu Z, Nettels D, Best RB, Schuler B. Disordered RNA chaperones can enhance nucleic acid folding via local charge screening. Nat Commun 2019;10:2453. [PMID: 31165735 DOI: 10.1038/s41467-019-10356-0] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 11.0] [Reference Citation Analysis]
34 Kanzaki N, Iwane S, Oeda S, Okada M, Kimura H, Eguchi Y, Fujimoto K. Categorization and Characterization of Activities Designed to Help Health-care Professionals Involved in Hepatitis Care Increase Their Awareness of the Disease: The Classification of Hepatitis Medical Care Coordinators. Intern Med 2019;58:1825-34. [PMID: 30799338 DOI: 10.2169/internalmedicine.1755-18] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
35 Li B, Li L, Peng Z, Liu D, Si L, Wang J, Yuan B, Huang J, Proksch P, Lin W. Harzianoic acids A and B, new natural scaffolds with inhibitory effects against hepatitis C virus. Bioorganic & Medicinal Chemistry 2019;27:560-7. [DOI: 10.1016/j.bmc.2018.12.038] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
36 Koh C, Dubey P, Han MAT, Walter PJ, Garraffo HM, Surana P, Southall NT, Borochov N, Uprichard SL, Cotler SJ, Etzion O, Heller T, Dahari H, Liang TJ. A randomized, proof-of-concept clinical trial on repurposing chlorcyclizine for the treatment of chronic hepatitis C. Antiviral Res 2019;163:149-55. [PMID: 30711416 DOI: 10.1016/j.antiviral.2019.01.017] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
37 Goel A, Ahmed A, Waked I. Clinical Epidemiology of Hepatitis C Virus. Clinical Epidemiology of Chronic Liver Diseases 2019. [DOI: 10.1007/978-3-319-94355-8_12] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
38 Rawla P, Sunkara T, Muralidharan P, Raj JP. Update in global trends and aetiology of hepatocellular carcinoma. Contemp Oncol (Pozn). 2018;22:141-150. [PMID: 30455585 DOI: 10.5114/wo.2018.78941] [Cited by in Crossref: 92] [Cited by in F6Publishing: 118] [Article Influence: 23.0] [Reference Citation Analysis]
39 Nguyen LN, Zhao J, Cao D, Dang X, Wang L, Lian J, Zhang Y, Jia Z, Wu XY, Morrison Z, Xie Q, Ji Y, Zhang Z, El Gazzar M, Ning S, Moorman JP, Yao ZQ. Inhibition of TRF2 accelerates telomere attrition and DNA damage in naïve CD4 T cells during HCV infection. Cell Death Dis 2018;9:900. [PMID: 30185784 DOI: 10.1038/s41419-018-0897-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
40 Sugiura A, Joshita S, Umemura T, Yamazaki T, Fujimori N, Kimura T, Matsumoto A, Igarashi K, Usami Y, Wada S, Mori H, Shibata S, Yoshizawa K, Morita S, Furuta K, Kamijo A, Iijima A, Kako S, Maruyama A, Kobayashi M, Komatsu M, Matsumura M, Miyabayashi C, Ichijo T, Takeuchi A, Koike Y, Gibo Y, Tsukadaira T, Inada H, Kiyosawa K, Tanaka E. Past history of hepatocellular carcinoma is an independent risk factor of treatment failure in patients with chronic hepatitis C virus infection receiving direct-acting antivirals. J Viral Hepat 2018;25:1462-71. [DOI: 10.1111/jvh.12973] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
41 Yang X, Ye Y, Wang T, Li M, Yu L, Xia M, Qian J, Hu Z. Eu3+ /Sm3+ dual-label time-resolved fluoroimmunoassay for measurement of hepatitis C virus antibodies. J Clin Lab Anal 2019;33:e22659. [PMID: 30152027 DOI: 10.1002/jcla.22659] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
42 Lee SH, Moon JS, Pak BY, Kim GW, Lee W, Cho H, Kim S, Kim SJ, Oh JW. HA1077 displays synergistic activity with daclatasvir against hepatitis C virus and suppresses the emergence of NS5A resistance-associated substitutions in mice. Sci Rep 2018;8:12469. [PMID: 30127498 DOI: 10.1038/s41598-018-30460-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
43 Duan X, Anwar MI, Xu Z, Ma L, Yuan G, Chen Y, Liu X, Xia J, Zhou Y, Li YP. Adaptive mutation F772S-enhanced p7-NS4A cooperation facilitates the assembly and release of hepatitis C virus and is associated with lipid droplet enlargement. Emerg Microbes Infect 2018;7:143. [PMID: 30087320 DOI: 10.1038/s41426-018-0140-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
44 Lei JH, Liang J, Gong X, Xiao XQ, Chen Z, Peng F. Analysis of Transmission Routes of Hepatitis C Virus Based on Virus Genotyping in 341 Cases with Different Suspected Initial Infection Time Points in Hunan Province, China. Med Sci Monit 2018;24:5232-41. [PMID: 30055000 DOI: 10.12659/MSM.907424] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
45 Tieu HV, Laeyendecker O, Nandi V, Rose R, Fernandez R, Lynch B, Hoover DR, Frye V, Koblin BA. Prevalence and mapping of hepatitis C infections among men who have sex with men in New York City. PLoS One 2018;13:e0200269. [PMID: 30020960 DOI: 10.1371/journal.pone.0200269] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
46 Ke R, Li H, Wang S, Ding W, Ribeiro RM, Giorgi EE, Bhattacharya T, Barnard RJO, Hahn BH, Shaw GM, Perelson AS. Superinfection and cure of infected cells as mechanisms for hepatitis C virus adaptation and persistence. Proc Natl Acad Sci U S A 2018;115:E7139-48. [PMID: 29987026 DOI: 10.1073/pnas.1805267115] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
47 Maekawa S, Enomoto N. The "real-world" efficacy and safety of DAAs for the treatment of HCV patients throughout Japan. J Gastroenterol 2018;53:1168-9. [PMID: 29980847 DOI: 10.1007/s00535-018-1493-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
48 Ruggeri M, Coretti S, Romano F, Kondili LA, Vella S, Cicchetti A. Economic Evaluation of the Hepatitis C Virus Treatment Extension to Early-Stage Fibrosis Patients: Evidence from the PITER Real-World Cohort. Value in Health 2018;21:783-91. [DOI: 10.1016/j.jval.2017.10.021] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
49 Shoukry NH. Hepatitis C Vaccines, Antibodies, and T Cells. Front Immunol 2018;9:1480. [PMID: 30002657 DOI: 10.3389/fimmu.2018.01480] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 12.3] [Reference Citation Analysis]
50 Dustin LB. Innate and Adaptive Immune Responses in Chronic HCV Infection. Curr Drug Targets 2017;18:826-43. [PMID: 26302811 DOI: 10.2174/1389450116666150825110532] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 8.8] [Reference Citation Analysis]
51 Guo Y, Yu H, Zhong Y, He Y, Qin X, Qin Y, Zhou Y, Zhang P, Zhang Y, Li Z, Jia Z. Lectin microarray and mass spectrometric analysis of hepatitis C proteins reveals N-linked glycosylation. Medicine (Baltimore) 2018;97:e0208. [PMID: 29642144 DOI: 10.1097/MD.0000000000010208] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
52 Zhang Z, Yin J, Yang J, Shen W, Zhang C, Mou W, Luo J, Yan H, Sun P, Luo Y, Tian Y, Xiang R. miR-885-5p suppresses hepatocellular carcinoma metastasis and inhibits Wnt/β-catenin signaling pathway. Oncotarget 2016;7:75038-51. [PMID: 27738331 DOI: 10.18632/oncotarget.12602] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 6.5] [Reference Citation Analysis]
53 Boudova S, Mark K, El-Kamary SS. Risk-Based Hepatitis C Screening in Pregnancy Is Less Reliable Than Universal Screening: A Retrospective Chart Review. Open Forum Infect Dis 2018;5:ofy043. [PMID: 29564364 DOI: 10.1093/ofid/ofy043] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 7.8] [Reference Citation Analysis]
54 Shan Z, Huang J, Liao Q, Huang K, Wang M, Xu R, Tang X, Zhang W, Nelson K, Fu Y, Li C, Rong X. Association of killer cell immunoglobulin-like receptors with spontaneous clearance of hepatitis C virus in the Chinese population. Transfusion 2018;58:1028-35. [PMID: 29446443 DOI: 10.1111/trf.14527] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
55 Jardim ACG, Shimizu JF, Rahal P, Harris M. Plant-derived antivirals against hepatitis c virus infection. Virol J 2018;15:34. [PMID: 29439720 DOI: 10.1186/s12985-018-0945-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
56 He CL, Liu M, Tan ZX, Hu YJ, Zhang QY, Kuang XM, Kong WL, Mao Q. Hepatitis C virus core protein-induced miR-93-5p up-regulation inhibits interferon signaling pathway by targeting IFNAR1. World J Gastroenterol 2018; 24(2): 226-236 [PMID: 29375208 DOI: 10.3748/wjg.v24.i2.226] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
57 Benbow JH, Elam AD, Bossi KL, Massengill DL, Brandon-Warner E, Anderson WE, Culberson CR, Russo MW, deLemos AS, Schrum LW. Analysis of Plasma Tenascin-C in Post-HCV Cirrhosis: A Prospective Study. Dig Dis Sci 2018;63:653-64. [PMID: 29330728 DOI: 10.1007/s10620-017-4860-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
58 El-Khayat H, Fouad Y, Mohamed HI, El-Amin H, Kamal EM, Maher M, Risk A. Sofosbuvir plus daclatasvir with or without ribavirin in 551 patients with hepatitis C-related cirrhosis, genotype 4. Aliment Pharmacol Ther. 2018;47:674-679. [PMID: 29314146 DOI: 10.1111/apt.14482] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 6.3] [Reference Citation Analysis]
59 Guo Z, Li J, Sun J, Sun L, Zhou Y, Yu Z. miR-346 Promotes HCC Progression by Suppressing Breast Cancer Metastasis Suppressor 1 Expression. Oncol Res 2018;26:1073-81. [PMID: 29295726 DOI: 10.3727/096504017X15145088802439] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
60 Froes-meyer P, Musa OM, Eltahir Saeed WS, Ahmed ME, Osman OA, Mohammed HK, Gasim Khalil EA. Biochemical aberrations, viral genotypic patterns and viral loads among Sudanese patients with chronic hepatitis C virus infection. JHVRV 2018;6:51-54. [DOI: 10.15406/jhvrv.2018.06.00195] [Reference Citation Analysis]
61 Smolders EJ, de Kanter CT, van Hoek B, Arends JE, Drenth JP, Burger DM. Pharmacokinetics, Efficacy, and Safety of Hepatitis C Virus Drugs in Patients with Liver and/or Renal Impairment. Drug Saf. 2016;39:589-611. [PMID: 27098247 DOI: 10.1007/s40264-016-0420-2] [Cited by in Crossref: 59] [Cited by in F6Publishing: 54] [Article Influence: 11.8] [Reference Citation Analysis]
62 Kondili LA, Romano F, Rolli FR, Ruggeri M, Rosato S, Brunetto MR, Zignego AL, Ciancio A, Di Leo A, Raimondo G, Ferrari C, Taliani G, Borgia G, Santantonio TA, Blanc P, Gaeta GB, Gasbarrini A, Chessa L, Erne EM, Villa E, Ieluzzi D, Russo FP, Andreone P, Vinci M, Coppola C, Chemello L, Madonia S, Verucchi G, Persico M, Zuin M, Puoti M, Alberti A, Nardone G, Massari M, Montalto G, Foti G, Rumi MG, Quaranta MG, Cicchetti A, Craxì A, Vella S; PITER Collaborating Group. Modeling cost-effectiveness and health gains of a "universal" versus "prioritized" hepatitis C virus treatment policy in a real-life cohort. Hepatology 2017;66:1814-25. [PMID: 28741307 DOI: 10.1002/hep.29399] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
63 Xu W, Flores-Mireles AL, Cusumano ZT, Takagi E, Hultgren SJ, Caparon MG. Host and bacterial proteases influence biofilm formation and virulence in a murine model of enterococcal catheter-associated urinary tract infection. NPJ Biofilms Microbiomes 2017;3:28. [PMID: 29134108 DOI: 10.1038/s41522-017-0036-z] [Cited by in Crossref: 36] [Cited by in F6Publishing: 41] [Article Influence: 7.2] [Reference Citation Analysis]
64 El-Khayat HR, Fouad YM, Maher M, El-Amin H, Muhammed H. Efficacy and safety of sofosbuvir plus simeprevir therapy in Egyptian patients with chronic hepatitis C: a real-world experience. Gut 2017;66:2008-12. [PMID: 27511197 DOI: 10.1136/gutjnl-2016-312012] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 4.8] [Reference Citation Analysis]
65 Dirani G, Paesini E, Mascetra E, Farabegoli P, Dalmo B, Bartolini B, Garbuglia AR, Capobianchi MR, Sambri V. A novel next generation sequencing assay as an alternative to currently available methods for hepatitis C virus genotyping. J Virol Methods 2018;251:88-91. [PMID: 29045810 DOI: 10.1016/j.jviromet.2017.10.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
66 Muzembo BA, Mbendi NC, Nakayama SF. Systematic review with meta-analysis: performance of dried blood spots for hepatitis C antibodies detection. Public Health 2017;153:128-36. [PMID: 29035801 DOI: 10.1016/j.puhe.2017.08.008] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
67 Lei JH, Gong X, Xiao XQ, Chen Z, Peng F. Genotype distribution of hepatitis C virus in 952 cases from 2014 to 2016 in Hunan Province, China. Arch Med Sci 2018;14:1055-60. [PMID: 30154888 DOI: 10.5114/aoms.2017.70664] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
68 Welzel TM, Nelson DR, Morelli G, Di Bisceglie A, Reddy RK, Kuo A, Lim JK, Darling J, Pockros P, Galati JS, Frazier LM, Alqahtani S, Sulkowski MS, Vainorius M, Akushevich L, Fried MW, Zeuzem S; HCV-TARGET Study Group. Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study. Gut 2017;66:1844-52. [PMID: 27418632 DOI: 10.1136/gutjnl-2016-311609] [Cited by in Crossref: 56] [Cited by in F6Publishing: 62] [Article Influence: 11.2] [Reference Citation Analysis]
69 Hai H, Tamori A, Thuy LTT, Yoshida K, Hagihara A, Kawamura E, Uchida-Kobayashi S, Morikawa H, Enomoto M, Murakami Y, Kawada N. Polymorphisms in MICA, but not in DEPDC5, HCP5 or PNPLA3, are associated with chronic hepatitis C-related hepatocellular carcinoma. Sci Rep 2017;7:11912. [PMID: 28928439 DOI: 10.1038/s41598-017-10363-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
70 Plissonnier ML, Lahlali T, Raab M, Michelet M, Romero-López C, Rivoire M, Strebhardt K, Durantel D, Levrero M, Mehlen P, Zoulim F, Parent R. Reciprocal antagonism between the netrin-1 receptor uncoordinated-phenotype-5A (UNC5A) and the hepatitis C virus. Oncogene 2017;36:6712-24. [PMID: 28783179 DOI: 10.1038/onc.2017.271] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
71 Tu T, Bühler S, Bartenschlager R. Chronic viral hepatitis and its association with liver cancer. Biol Chem 2017;398:817-37. [PMID: 28455951 DOI: 10.1515/hsz-2017-0118] [Cited by in Crossref: 58] [Cited by in F6Publishing: 62] [Article Influence: 11.6] [Reference Citation Analysis]
72 Gao R, Gao W, Xu G, Xu J, Ren H. Single amino acid mutation of SR-BI decreases infectivity of hepatitis C virus derived from cell culture in a cell culture model. World J Gastroenterol 2017; 23(28): 5158-5166 [PMID: 28811710 DOI: 10.3748/wjg.v23.i28.5158] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
73 Wang Z, Gao Y, Zhang C, Hu H, Guo D, Xu Y, Xu Q, Zhang W, Deng S, Lv P, Yang Y, Ding Y, Li Q, Weng C, Chen X, Gong S, Chen H, Niu J, Tang H. Quinolinate Phosphoribosyltransferase is an Antiviral Host Factor Against Hepatitis C Virus Infection. Sci Rep 2017;7:5876. [PMID: 28724915 DOI: 10.1038/s41598-017-06254-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
74 Madhvi A, Hingane S, Srivastav R, Joshi N, Subramani C, Muthumohan R, Khasa R, Varshney S, Kalia M, Vrati S, Surjit M, Ranjith-Kumar CT. A screen for novel hepatitis C virus RdRp inhibitor identifies a broad-spectrum antiviral compound. Sci Rep 2017;7:5816. [PMID: 28725041 DOI: 10.1038/s41598-017-04449-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
75 Welzel TM, Hinrichsen H, Sarrazin C, Buggisch P, Baumgarten A, Christensen S, Berg T, Mauss S, Teuber G, Stein K, Deterding K, van Bömmel F, Heyne R, John C, Zimmermann T, Lutz T, Schott E, Hettinger J, Kleine H, König B, Hüppe D, Wedemeyer H. Real-world experience with the all-oral, interferon-free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German Hepatitis C Registry. J Viral Hepat 2017;24:840-9. [DOI: 10.1111/jvh.12708] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 7.2] [Reference Citation Analysis]
76 Ramos H, Linares P, Badia E, Martín I, Gómez J, Almohalla C, Jorquera F, Calvo S, García I, Conde P, Álvarez B, Karpman G, Lorenzo S, Gozalo V, Vásquez M, Joao D, de Benito M, Ruiz L, Jiménez F, Sáez-Royuela F, Asociación Castellano y Leonesa de Hepatología (ACyLHE). Interferon-free treatments in patients with hepatitis C genotype 1-4 infections in a real-world setting. World J Gastrointest Pharmacol Ther 2017; 8(2): 137-146 [PMID: 28533924 DOI: 10.4292/wjgpt.v8.i2.137] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
77 Ventura M, Martin L, Jaubert C, Andréola M, Masante C. Hepatitis C virus intragenomic interactions are modulated by the SLVI RNA structure of the core coding sequence. Journal of General Virology 2017;98:633-42. [DOI: 10.1099/jgv.0.000719] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
78 Ueda Y, Dansako H, Satoh S, Kim HS, Wataya Y, Doi H, Ikeda M, Kato N. Evaluation of preclinical antimalarial drugs, which can overcome direct-acting antivirals-resistant hepatitis C viruses, using the viral reporter assay systems. Virus Res 2017;235:37-48. [PMID: 28322919 DOI: 10.1016/j.virusres.2017.03.015] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
79 Lei JH, Yang X, Xiao XQ, Chen Z, Peng F. A preliminary investigation on single nucleotide polymorphism rs2287622 of bile salt export pump gene in patients with chronic hepatitis C virus infection in Hunan, China. BMC Gastroenterol 2017;17:42. [PMID: 28292275 DOI: 10.1186/s12876-017-0594-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
80 Baumert TF, Jühling F, Ono A, Hoshida Y. Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals. BMC Med 2017;15:52. [PMID: 28288626 DOI: 10.1186/s12916-017-0815-7] [Cited by in Crossref: 94] [Cited by in F6Publishing: 96] [Article Influence: 18.8] [Reference Citation Analysis]
81 Lévy PL, Duponchel S, Eischeid H, Molle J, Michelet M, Diserens G, Vermathen M, Vermathen P, Dufour JF, Dienes HP, Steffen HM, Odenthal M, Zoulim F, Bartosch B. Hepatitis C virus infection triggers a tumor-like glutamine metabolism. Hepatology 2017;65:789-803. [PMID: 27863447 DOI: 10.1002/hep.28949] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 6.6] [Reference Citation Analysis]
82 Zhang Y, Chen LM, He M. Hepatitis C Virus in mainland China with an emphasis on genotype and subtype distribution. Virol J. 2017;14:41. [PMID: 28231805 DOI: 10.1186/s12985-017-0710-z] [Cited by in Crossref: 52] [Cited by in F6Publishing: 60] [Article Influence: 10.4] [Reference Citation Analysis]
83 Gupta E, Agarwala P, Kumar G, Maiwall R, Sarin SK. Point -of -care testing (POCT) in molecular diagnostics: Performance evaluation of GeneXpert HCV RNA test in diagnosing and monitoring of HCV infection. J Clin Virol 2017;88:46-51. [PMID: 28160728 DOI: 10.1016/j.jcv.2017.01.006] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 9.2] [Reference Citation Analysis]
84 Zimmermann A. Etiology and Pathogenesis of Hepatocellular Carcinoma: Inflammatory and Toxic Causes. Tumors and Tumor-Like Lesions of the Hepatobiliary Tract 2017. [DOI: 10.1007/978-3-319-26956-6_164] [Reference Citation Analysis]
85 Rosen HR. "Hep C, where art thou": What are the remaining (fundable) questions in hepatitis C virus research? Hepatology 2017;65:341-9. [PMID: 27640881 DOI: 10.1002/hep.28848] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
86 Ahlén G, Frelin L. Methods to Evaluate Novel Hepatitis C Virus Vaccines. Methods Mol Biol 2016;1403:221-44. [PMID: 27076133 DOI: 10.1007/978-1-4939-3387-7_11] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
87 Walter S, Rasche A, Moreira-Soto A, Pfaender S, Bletsa M, Corman VM, Aguilar-Setien A, García-Lacy F, Hans A, Todt D, Schuler G, Shnaiderman-Torban A, Steinman A, Roncoroni C, Veneziano V, Rusenova N, Sandev N, Rusenov A, Zapryanova D, García-Bocanegra I, Jores J, Carluccio A, Veronesi MC, Cavalleri JMV, Drosten C, Lemey P, Steinmann E, Drexler JF. Differential Infection Patterns and Recent Evolutionary Origins of Equine Hepaciviruses in Donkeys. J Virol 2017;91:e01711-16. [PMID: 27795428 DOI: 10.1128/JVI.01711-16] [Cited by in Crossref: 30] [Cited by in F6Publishing: 35] [Article Influence: 5.0] [Reference Citation Analysis]
88 Moore TO, Paradowski M, Ward SE. An atom-efficient and convergent approach to the preparation of NS5A inhibitors by C-H activation. Org Biomol Chem 2016;14:3307-13. [PMID: 26936019 DOI: 10.1039/c6ob00340k] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
89 Zhang Q, Matsuura K, Kleiner DE, Zamboni F, Alter HJ, Farci P. Analysis of long noncoding RNA expression in hepatocellular carcinoma of different viral etiology. J Transl Med. 2016;14:328. [PMID: 27894309 DOI: 10.1186/s12967-016-1085-4] [Cited by in Crossref: 43] [Cited by in F6Publishing: 45] [Article Influence: 7.2] [Reference Citation Analysis]
90 Pronost S, Hue E, Fortier C, Foursin M, Fortier G, Desbrosse F, Rey FA, Pitel PH, Richard E, Saunier B. Prevalence of Equine Hepacivirus Infections in France and Evidence for Two Viral Subtypes Circulating Worldwide. Transbound Emerg Dis 2017;64:1884-97. [PMID: 27882682 DOI: 10.1111/tbed.12587] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
91 Goossens N, Hoshida Y. Tratamiento personalizado del carcinoma hepatocelular basado en información molecular: perspectivas futuras. Clin Liver Dis (Hoboken) 2016;8:S43-8. [PMID: 31041096 DOI: 10.1002/cld.601] [Reference Citation Analysis]
92 Ogawa E, Furusyo N, Nomura H, Takahashi K, Higashi N, Kawano A, Dohmen K, Satoh T, Azuma K, Nakamuta M, Koyanagi T, Kato M, Shimoda S, Kajiwara E, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group. Effectiveness and safety of sofosbuvir plus ribavirin for HCV genotype 2 patients 65 and over with or without cirrhosis. Antiviral Res. 2016;136:37-44. [PMID: 27789224 DOI: 10.1016/j.antiviral.2016.10.012] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 6.2] [Reference Citation Analysis]
93 Taaffe J, Wilson D. Mobilising a global response to hepatitis: Lessons learned from the HIV movement. Glob Public Health 2018;13:473-88. [PMID: 27748158 DOI: 10.1080/17441692.2016.1233989] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
94 Smith DJ, Jordan AE, Frank M, Hagan H. Spontaneous viral clearance of hepatitis C virus (HCV) infection among people who inject drugs (PWID) and HIV-positive men who have sex with men (HIV+ MSM): a systematic review and meta-analysis. BMC Infect Dis 2016;16:471. [PMID: 27595855 DOI: 10.1186/s12879-016-1807-5] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 5.5] [Reference Citation Analysis]
95 Houldsworth A. Exploring the possibility of arthropod transmission of HCV. J Med Virol 2017;89:187-94. [PMID: 27447819 DOI: 10.1002/jmv.24638] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
96 Li W, Xiao F, Zhou M, Jiang X, Liu J, Si H, Xie M, Ma X, Duan Y, Zhai H. 3D-QSAR study and design of 4-hydroxyamino α-pyranone carboxamide analogues as potential anti-HCV agents. Chemical Physics Letters 2016;661:36-41. [DOI: 10.1016/j.cplett.2016.08.042] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
97 Dustin LB, Bartolini B, Capobianchi MR, Pistello M. Hepatitis C virus: life cycle in cells, infection and host response, and analysis of molecular markers influencing the outcome of infection and response to therapy. Clin Microbiol Infect 2016;22:826-32. [PMID: 27592089 DOI: 10.1016/j.cmi.2016.08.025] [Cited by in Crossref: 52] [Cited by in F6Publishing: 53] [Article Influence: 8.7] [Reference Citation Analysis]
98 Borgia G, Maraolo AE, Buonomo AR, Scotto R, Gentile I. The therapeutic potential of new investigational hepatitis C virus translation inhibitors. Expert Opin Investig Drugs 2016;25:1209-14. [PMID: 27537604 DOI: 10.1080/13543784.2016.1225036] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
99 Armstrong AR, Herrmann SE, Chassany O, Lalanne C, Da Silva MH, Galano E, Carrieri PM, Estellon V, Sogni P, Duracinsky M. The International development of PROQOL-HCV: An instrument to assess the health-related quality of life of patients treated for Hepatitis C virus. BMC Infect Dis 2016;16:443. [PMID: 27553866 DOI: 10.1186/s12879-016-1771-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
100 Daw MA, El-Bouzedi A, Ahmed MO, Dau AA, Agnan MM. Hepatitis C Virus in North Africa: An Emerging Threat. ScientificWorldJournal 2016;2016:7370524. [PMID: 27610403 DOI: 10.1155/2016/7370524] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
101 Huang J, Huang K, Xu R, Wang M, Liao Q, Xiong H, Li C, Tang X, Shan Z, Zhang M, Rong X, Nelson K, Fu Y. The Associations of HLA-A*02:01 and DRB1*11:01 with Hepatitis C Virus Spontaneous Clearance Are Independent of IL28B in the Chinese Population. Sci Rep 2016;6:31485. [PMID: 27511600 DOI: 10.1038/srep31485] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
102 Daw MA, El-Bouzedi A, Ahmed MO, Dau AA, Agnan MM; In association with the Libyan Study Group of Hepatitis & amp; HIV. Epidemiology of hepatitis C virus and genotype distribution in immigrants crossing to Europe from North and sub-Saharan Africa. Travel Med Infect Dis. 2016;14:517-526. [PMID: 27502972 DOI: 10.1016/j.tmaid.2016.05.020] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
103 Lin Y, Shaw TG, Yang H, Lu S, Jen C, Wang L, Wong K, Chan S, Yuan Y, L'italien G, Chen C, Lee M; the R.E.V.E.A.L.-HCV Study Group. Chronic hepatitis C virus infection and the risk for diabetes: a community-based prospective study. Liver Int 2017;37:179-86. [DOI: 10.1111/liv.13194] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 4.7] [Reference Citation Analysis]
104 Qian XJ, Zhang XL, Zhao P, Jin YS, Chen HS, Xu QQ, Ren H, Zhu SY, Tang HL, Zhu YZ. A Schisandra-Derived Compound Schizandronic Acid Inhibits Entry of Pan-HCV Genotypes into Human Hepatocytes. Sci Rep. 2016;6:27268. [PMID: 27252043 DOI: 10.1038/srep27268] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
105 Meyers NL, Fontaine KA, Kumar GR, Ott M. Entangled in a membranous web: ER and lipid droplet reorganization during hepatitis C virus infection. Curr Opin Cell Biol 2016;41:117-24. [PMID: 27240021 DOI: 10.1016/j.ceb.2016.05.003] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
106 Sikorska K. The iron homeostasis network and hepatitis C virus - a new challenge in the era of directly acting antivirals. Virulence. 2016;7:620-622. [PMID: 27196953 DOI: 10.1080/21505594.2016.1191739] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
107 Qian X, Jin Y, Chen H, Xu Q, Ren H, Zhu S, Tang H, Wang Y, Zhao P, Qi Z, Zhu Y. Trachelogenin, a novel inhibitor of hepatitis C virus entry through CD81. Journal of General Virology 2016;97:1134-44. [DOI: 10.1099/jgv.0.000432] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
108 Levander S, Sällberg M, Ahlén G, Frelin L. A non-human hepadnaviral adjuvant for hepatitis C virus-based genetic vaccines. Vaccine 2016;34:2821-33. [PMID: 27109565 DOI: 10.1016/j.vaccine.2016.04.030] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
109 Araujo Martins AM. Molecular Events of Hepatitis C in Hepatocellular Carcinoma. GHOA 2016;4. [DOI: 10.15406/ghoa.2016.04.00108] [Reference Citation Analysis]
110 Mallory M, Hillyard D. Hepatitis C Virus. Clinical Virology Manual 2016. [DOI: 10.1128/9781555819156.ch25] [Reference Citation Analysis]
111 Colpitts CC, Baumert TF. Hepatitis C virus cell entry: a target for novel antiviral strategies to address limitations of direct acting antivirals. Hepatol Int 2016;10:741-8. [DOI: 10.1007/s12072-016-9724-7] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.7] [Reference Citation Analysis]
112 Cao Y, Bao Y, Xia W, Wu H, Wei F, Zhang Y, Zhang R, Xu X. Resistance-associated mutations to HCV protease inhibitors naturally pre-existed in HIV/HCV coinfected, treatment-naïve patients. Clin Res Hepatol Gastroenterol 2016;40:597-604. [PMID: 27016893 DOI: 10.1016/j.clinre.2016.02.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
113 Moon JS, Lee SH, Han SH, Kim EJ, Cho H, Lee W, Kim MK, Kim TE, Park HJ, Rhee JK, Kim SJ, Cho SW, Han SH, Oh JW. Inhibition of hepatitis C virus in mouse models by lipidoid nanoparticle-mediated systemic delivery of siRNA against PRK2. Nanomedicine 2016;12:1489-98. [PMID: 27013134 DOI: 10.1016/j.nano.2016.02.015] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
114 Li Y, Wang R, Du X, Zhang M, Xie M. Genome-wide analysis for identification of adaptive diversification between hepatitis C virus subtypes 1a and 1b. Can J Microbiol 2016;62:608-16. [PMID: 27277863 DOI: 10.1139/cjm-2016-0156] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
115 Su TH, Liu CJ, Tseng TC, Chou SW, Liu CH, Yang HC, Wu SJ, Chen PJ, Chen DS, Chen CL, Kao JH. Hepatitis C viral infection increases the risk of lymphoid-neoplasms: A population-based cohort study. Hepatology 2016;63:721-30. [PMID: 26662347 DOI: 10.1002/hep.28387] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 5.7] [Reference Citation Analysis]
116 Tsertsvadze T, Sharvadze L, Chkhartishvili N, Dzigua L, Karchava M, Gatserelia L, Abutidze A, Nelson KE. The natural history of recent hepatitis C virus infection among blood donors and injection drug users in the country of Georgia. Virol J 2016;13:22. [PMID: 26843145 DOI: 10.1186/s12985-016-0478-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
117 Zhang L, Celentano DD, Le Minh N, Latkin CA, Mehta SH, Frangakis C, Ha TV, Mo TT, Sripaipan T, Davis WW. Prevalence and correlates of HCV monoinfection and HIV and HCV coinfection among persons who inject drugs in Vietnam. Eur J Gastroenterol Hepatol. 2015;27:550-556. [PMID: 25769097 DOI: 10.1097/meg.0000000000000321] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
118 He S, Xiao J, Dulcey AE, Lin B, Rolt A, Hu Z, Hu X, Wang AQ, Xu X, Southall N, Ferrer M, Zheng W, Liang TJ, Marugan JJ. Discovery, Optimization, and Characterization of Novel Chlorcyclizine Derivatives for the Treatment of Hepatitis C Virus Infection. J Med Chem 2016;59:841-53. [PMID: 26599718 DOI: 10.1021/acs.jmedchem.5b00752] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
119 Bretaña NA, Boelen L, Bull R, Teutsch S, White PA, Lloyd AR, Luciani F; HITS-p investigators. Transmission of Hepatitis C Virus among Prisoners, Australia, 2005-2012. Emerg Infect Dis 2015;21:765-74. [PMID: 25897788 DOI: 10.3201/eid2105.141832] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 5.8] [Reference Citation Analysis]
120 Dai R, Xiao X, Peng F, Li M, Gong G. Artesunate, an anti-malarial drug, has a potential to inhibit HCV replication. Virus Genes 2016;52:22-8. [PMID: 26739460 DOI: 10.1007/s11262-015-1285-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
121 He S, Lin B, Chu V, Hu Z, Hu X, Xiao J, Wang AQ, Schweitzer CJ, Li Q, Imamura M, Hiraga N, Southall N, Ferrer M, Zheng W, Chayama K, Marugan JJ, Liang TJ. Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infection. Sci Transl Med 2015;7:282ra49. [PMID: 25855495 DOI: 10.1126/scitranslmed.3010286] [Cited by in Crossref: 99] [Cited by in F6Publishing: 104] [Article Influence: 16.5] [Reference Citation Analysis]
122 Hafid AF, Permanasari AA, Tumewu L, Adianti M, Aoki C, Widyawaruyanti A, Soetjipto, Lusida MI, Hotta H. Activities of Ficus fistulosa Leave Extract and Fractions against Hepatitis C Virus. Procedia Chemistry 2016;18:179-84. [DOI: 10.1016/j.proche.2016.01.028] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
123 Miyamura T. Global Control of Hepatitis C Virus Infection. Hepatitis C Virus II 2016. [DOI: 10.1007/978-4-431-56101-9_14] [Reference Citation Analysis]
124 Zimmermann A. Etiology and Pathogenesis of Hepatocellular Carcinoma: Inflammatory and Toxic Causes. Tumors and Tumor-Like Lesions of the Hepatobiliary Tract 2016. [DOI: 10.1007/978-3-319-26587-2_164-1] [Reference Citation Analysis]
125 Rickinson A, Easom N, Maini M, Rowe M. Immunity to Oncogenic Viruses. Encyclopedia of Immunobiology 2016. [DOI: 10.1016/b978-0-12-374279-7.14025-1] [Reference Citation Analysis]
126 Chong WM, Hsu SC, Kao WT, Lo CW, Lee KY, Shao JS, Chen YH, Chang J, Chen SS, Yu MJ. Phosphoproteomics Identified an NS5A Phosphorylation Site Involved in Hepatitis C Virus Replication. J Biol Chem 2016;291:3918-31. [PMID: 26702051 DOI: 10.1074/jbc.M115.675413] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
127 Mailly L, Zeisel MB, Baumert TF. Enfermé dehors: Traitement de l’hépatite C chronique par un inhibiteur d’entrée. Med Sci (Paris) 2015;31:1075-7. [DOI: 10.1051/medsci/20153112009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
128 Soriano V, Labarga P, de Mendoza C, Fernández-Montero JV, Esposito I, Benítez-Gutiérrez L, Peña JM, Barreiro P. New hepatitis C therapies for special patient populations. Expert Opin Pharmacother 2016;17:217-29. [PMID: 26595348 DOI: 10.1517/14656566.2016.1112790] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
129 Gondeau C, Pageaux GP, Larrey D. Hepatitis C virus infection: Are there still specific problems with genotype 3? World J Gastroenterol 2015; 21(42): 12101-12113 [PMID: 26576095 DOI: 10.3748/wjg.v21.i42.12101] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
130 Gbandi E, Goulas A, Sevastianos V, Hadziyannis S, Panderi A, Koskinas J, Papatheodoridis G, Vasiliadis T, Agapakis D, Protopapas A, Ioannidou P, Zacharakis G, Sinakos E, Koutsounas S, Germanidis G. Common ABCB1 polymorphisms in Greek patients with chronic hepatitis C infection: A comparison with hyperlipidemic patients and the general population. Pharmacol Rep 2016;68:476-82. [PMID: 26922556 DOI: 10.1016/j.pharep.2015.10.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
131 Lu YF, Mauger DM, Goldstein DB, Urban TJ, Weeks KM, Bradrick SS. IFNL3 mRNA structure is remodeled by a functional non-coding polymorphism associated with hepatitis C virus clearance. Sci Rep. 2015;5:16037. [PMID: 26531896 DOI: 10.1038/srep16037] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 5.7] [Reference Citation Analysis]
132 Murira A, Lapierre P, Lamarre A. Evolution of the Humoral Response during HCV Infection: Theories on the Origin of Broadly Neutralizing Antibodies and Implications for Vaccine Design. Adv Immunol 2016;129:55-107. [PMID: 26791858 DOI: 10.1016/bs.ai.2015.09.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
133 Sulkowski MS, Vargas HE, Di Bisceglie AM, Kuo A, Reddy KR, Lim JK, Morelli G, Darling JM, Feld JJ, Brown RS, Frazier LM, Stewart TG, Fried MW, Nelson DR, Jacobson IM; HCV-TARGET Study Group. Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection. Gastroenterology 2016;150:419-29. [PMID: 26497081 DOI: 10.1053/j.gastro.2015.10.013] [Cited by in Crossref: 140] [Cited by in F6Publishing: 148] [Article Influence: 20.0] [Reference Citation Analysis]
134 Colpitts CC, Baumert TF. Viral hepatitis: A new HCV cell culture model for the next clinical challenges. Nat Rev Gastroenterol Hepatol 2015;12:611-3. [PMID: 26441247 DOI: 10.1038/nrgastro.2015.170] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
135 Sizun G, Pierra C, Peyronnet J, Badaroux E, Rabeson C, Benzaria-Prad S, Surleraux D, Loi AG, Musiu C, Liuzzi M, Seifer M, Standring D, Sommadossi JP, Gosselin G. Design, synthesis and antiviral evaluation of 2'-C-methyl branched guanosine pronucleotides: the discovery of IDX184, a potent liver-targeted HCV polymerase inhibitor. Future Med Chem 2015;7:1675-700. [PMID: 26424162 DOI: 10.4155/fmc.15.96] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
136 Goossens N, Sun X, Hoshida Y. Molecular classification of hepatocellular carcinoma: potential therapeutic implications. Hepat Oncol 2015;2:371-9. [PMID: 26617981 DOI: 10.2217/hep.15.26] [Cited by in Crossref: 71] [Cited by in F6Publishing: 76] [Article Influence: 10.1] [Reference Citation Analysis]
137 Narayana SK, Helbig KJ, McCartney EM, Eyre NS, Bull RA, Eltahla A, Lloyd AR, Beard MR. The Interferon-induced Transmembrane Proteins, IFITM1, IFITM2, and IFITM3 Inhibit Hepatitis C Virus Entry. J Biol Chem 2015;290:25946-59. [PMID: 26354436 DOI: 10.1074/jbc.M115.657346] [Cited by in Crossref: 89] [Cited by in F6Publishing: 90] [Article Influence: 12.7] [Reference Citation Analysis]
138 Kondili LA, Vella S. PITER: An ongoing nationwide study on the real-life impact of direct acting antiviral based treatment for chronic hepatitis C in Italy. Digestive and Liver Disease 2015;47:741-3. [DOI: 10.1016/j.dld.2015.05.022] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
139 Szabo SM, Samp JC, Walker DR, Lane S, Cline SK, Gooch KL, Jimenez-mendez R, Levy AR. Liver-specific case fatality due to chronic hepatitis C virus infection: A systematic review. Annals of Hepatology 2015;14:618-30. [DOI: 10.1016/s1665-2681(19)30756-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
140 Zhang J, Garrison JC, Poluektova LY, Bronich TK, Osna NA. Liver-targeted antiviral peptide nanocomplexes as potential anti-HCV therapeutics. Biomaterials 2015;70:37-47. [PMID: 26298393 DOI: 10.1016/j.biomaterials.2015.08.014] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
141 Ploen D, Hildt E. Hepatitis C virus comes for dinner: How the hepatitis C virus interferes with autophagy. World J Gastroenterol 2015; 21(28): 8492-8507 [PMID: 26229393 DOI: 10.3748/wjg.v21.i28.8492] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
142 Ke R, Loverdo C, Qi H, Sun R, Lloyd-Smith JO. Rational Design and Adaptive Management of Combination Therapies for Hepatitis C Virus Infection. PLoS Comput Biol 2015;11:e1004040. [PMID: 26125950 DOI: 10.1371/journal.pcbi.1004040] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
143 Goossens N, Hoshida Y. Personalized management of hepatocellular carcinoma based on molecular information: future prospects. Clin Liver Dis (Hoboken) 2015;5:132-5. [PMID: 26213619 DOI: 10.1002/cld.483] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
144 Huang QT, Huang Q, Zhong M, Wei SS, Luo W, Li F, Yu YH. Chronic hepatitis C virus infection is associated with increased risk of preterm birth: a meta-analysis of observational studies. J Viral Hepat 2015;22:1033-42. [PMID: 26081198 DOI: 10.1111/jvh.12430] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 5.0] [Reference Citation Analysis]
145 Tong YQ, Liu B, Liu H, Zheng HY, Gu J, Liu H, Song EJ, Song C, Li Y. Accurate genotyping of hepatitis C virus through nucleotide sequencing and identification of new HCV subtypes in China population. Clin Microbiol Infect 2015;21:874.e9-874.e21. [PMID: 26055416 DOI: 10.1016/j.cmi.2015.05.034] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
146 Bartosch B. Piecing together the key players of fibrosis in chronic hepatitis C: what roles do non-hepatic liver resident cell types play? Gut 2015;64:862-3. [PMID: 25200745 DOI: 10.1136/gutjnl-2014-307957] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
147 Bansal R, Frelin L, Brenndörfer ED, Storm G, Prakash J, Sällberg M. Hepatitis C Virus Nonstructural 3/4A Protein Dampens Inflammation and Contributes to Slow Fibrosis Progression during Chronic Fibrosis In Vivo. PLoS One 2015;10:e0128466. [PMID: 26030283 DOI: 10.1371/journal.pone.0128466] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
148 Herzer K, Papadopoulos-Köhn A, Achterfeld A, Canbay A, Piras-Straub K, Paul A, Walker A, Timm J, Gerken G. Management of telaprevir-based triple therapy for hepatitis C virus recurrence post liver transplant. World J Hepatol 2015; 7(9): 1287-1296 [PMID: 26019745 DOI: 10.4254/wjh.v7.i9.1287] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
149 Xiong W, Yang J, Wang M, Wang H, Rao Z, Zhong C, Xin X, Mo L, Yu S, Shen C, Zheng C. Vinexin β Interacts with Hepatitis C Virus NS5A, Modulating Its Hyperphosphorylation To Regulate Viral Propagation. J Virol 2015;89:7385-400. [PMID: 25972535 DOI: 10.1128/JVI.00567-15] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
150 Takayama K, Furusyo N, Ogawa E, Ikezaki H, Shimizu M, Murata M, Hayashi J. Direct-acting antiviral-based triple therapy on alpha-fetoprotein level in chronic hepatitis C patients. World J Gastroenterol 2015; 21(15): 4696-4706 [PMID: 25914481 DOI: 10.3748/wjg.v21.i15.4696] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
151 Ferenci P. Treatment of hepatitis C in difficult-to-treat patients. Nat Rev Gastroenterol Hepatol. 2015;12:284-292. [PMID: 25895822 DOI: 10.1038/nrgastro.2015.53] [Cited by in Crossref: 56] [Cited by in F6Publishing: 58] [Article Influence: 8.0] [Reference Citation Analysis]
152 Niu Y, Si Y, Li Y, Chi X, Li X, Liu X, Li D, Cheng M, Fan J, Si S, Yang W. A novel small-molecule inhibitor of hepatitis C virus replication acts by suppressing signal transducer and activator of transcription 3. J Antimicrob Chemother 2015;70:2013-23. [PMID: 25858355 DOI: 10.1093/jac/dkv077] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
153 Robinson MW, Aranday-Cortes E, Gatherer D, Swann R, Liefhebber JM, Filipe Ada S, Sigruener A, Barclay ST, Mills PR, Patel AH. Viral genotype correlates with distinct liver gene transcription signatures in chronic hepatitis C virus infection. Liver Int. 2015;35:2256-2264. [PMID: 25800823 DOI: 10.1111/liv.12830] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
154 Mailly L, Xiao F, Lupberger J, Wilson GK, Aubert P, Duong FHT, Calabrese D, Leboeuf C, Fofana I, Thumann C, Bandiera S, Lütgehetmann M, Volz T, Davis C, Harris HJ, Mee CJ, Girardi E, Chane-Woon-Ming B, Ericsson M, Fletcher N, Bartenschlager R, Pessaux P, Vercauteren K, Meuleman P, Villa P, Kaderali L, Pfeffer S, Heim MH, Neunlist M, Zeisel MB, Dandri M, McKeating JA, Robinet E, Baumert TF. Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody. Nat Biotechnol 2015;33:549-54. [PMID: 25798937 DOI: 10.1038/nbt.3179] [Cited by in Crossref: 110] [Cited by in F6Publishing: 113] [Article Influence: 15.7] [Reference Citation Analysis]
155 Isken O, Langerwisch U, Jirasko V, Rehders D, Redecke L, Ramanathan H, Lindenbach BD, Bartenschlager R, Tautz N. A conserved NS3 surface patch orchestrates NS2 protease stimulation, NS5A hyperphosphorylation and HCV genome replication. PLoS Pathog 2015;11:e1004736. [PMID: 25774920 DOI: 10.1371/journal.ppat.1004736] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
156 Galbraith JW, Franco RA, Donnelly JP, Rodgers JB, Morgan JM, Viles AF, Overton ET, Saag MS, Wang HE. Unrecognized chronic hepatitis C virus infection among baby boomers in the emergency department. Hepatology 2015;61:776-82. [PMID: 25179527 DOI: 10.1002/hep.27410] [Cited by in Crossref: 96] [Cited by in F6Publishing: 100] [Article Influence: 13.7] [Reference Citation Analysis]
157 Shrivastava S, Steele R, Ray R, Ray RB. MicroRNAs: Role in Hepatitis C Virus pathogenesis. Genes Dis. 2015;2:35-45. [PMID: 25984557 DOI: 10.1016/j.gendis.2015.01.001] [Cited by in Crossref: 54] [Cited by in F6Publishing: 59] [Article Influence: 7.7] [Reference Citation Analysis]
158 Calabrese LH, Cacoub PP. For patients with rheumatic disease and hepatitis C infection: the end of interferon. RMD Open 2015;1:e000008. [PMID: 26509045 DOI: 10.1136/rmdopen-2014-000008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
159 Li Y, Yamane D, Lemon SM. Dissecting the roles of the 5' exoribonucleases Xrn1 and Xrn2 in restricting hepatitis C virus replication. J Virol. 2015;89:4857-4865. [PMID: 25673723 DOI: 10.1128/jvi.03692-14] [Cited by in Crossref: 52] [Cited by in F6Publishing: 53] [Article Influence: 7.4] [Reference Citation Analysis]
160 Masaki T, Arend KC, Li Y, Yamane D, McGivern DR, Kato T, Wakita T, Moorman NJ, Lemon SM. miR-122 stimulates hepatitis C virus RNA synthesis by altering the balance of viral RNAs engaged in replication versus translation. Cell Host Microbe 2015;17:217-28. [PMID: 25662750 DOI: 10.1016/j.chom.2014.12.014] [Cited by in Crossref: 102] [Cited by in F6Publishing: 106] [Article Influence: 14.6] [Reference Citation Analysis]
161 Henderson JA, Bilimoria D, Bubenik M, Cadilhac C, Cottrell KM, Dietrich E, Denis F, Ewing N, Falardeau G, Giroux S, Grey R, L’heureux L, Liu B, Mani N, Morris M, Nicolas O, Pereira OZ, Poisson C, Govinda Rao B, Reddy TJ, Selliah S, Shawgo RS, Vaillancourt L, Wang J, Yannopoulos CG, Chauret N, Berlioz-seux F, Chan LC, Das SK, Grillot A, Bennani YL, Maxwell JP. Benzimidazole-containing HCV NS5A inhibitors: Effect of 4-substituted pyrrolidines in balancing genotype 1a and 1b potency. Bioorganic & Medicinal Chemistry Letters 2015;25:944-7. [DOI: 10.1016/j.bmcl.2014.12.045] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
162 Lemoine M, Eholié S, Lacombe K. Reducing the neglected burden of viral hepatitis in Africa: Strategies for a global approach. Journal of Hepatology 2015;62:469-76. [DOI: 10.1016/j.jhep.2014.10.008] [Cited by in Crossref: 90] [Cited by in F6Publishing: 104] [Article Influence: 12.9] [Reference Citation Analysis]
163 Giroux S, Bilimoria D, Cadilhac C, Cottrell KM, Denis F, Dietrich E, Ewing N, Henderson JA, L’heureux L, Mani N, Morris M, Nicolas O, Reddy TJ, Selliah S, Shawgo RS, Xu J, Chauret N, Berlioz-seux F, Chan LC, Das SK, Grillot A, Bennani YL, Maxwell JP. Discovery of thienoimidazole-based HCV NS5A inhibitors. Part 1: C2-Symmetric inhibitors with diyne and biphenyl linkers. Bioorganic & Medicinal Chemistry Letters 2015;25:936-9. [DOI: 10.1016/j.bmcl.2014.12.046] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
164 Hedenstierna M, Weiland O, Brass A, Bankwitz D, Behrendt P, Uhnoo I, Aleman S, Cardell K, Fryden A, Norkrans G, Eilard A, Glaumann H, Pietschmann T, Sällberg M, Brenndörfer ED. Long-term follow-up of successful hepatitis C virus therapy: waning immune responses and disappearance of liver disease are consistent with cure. Aliment Pharmacol Ther 2015;41:532-43. [PMID: 25627143 DOI: 10.1111/apt.13096] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
165 Anggakusuma, Frentzen A, Gürlevik E, Yuan Q, Steinmann E, Ott M, Staeheli P, Schmid-Burgk J, Schmidt T, Hornung V, Kuehnel F, Pietschmann T. Control of hepatitis C virus replication in mouse liver-derived cells by MAVS-dependent production of type I and type III interferons. J Virol 2015;89:3833-45. [PMID: 25609814 DOI: 10.1128/JVI.03129-14] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
166 Mukherjee A, Di Bisceglie AM, Ray RB. Hepatitis C virus-mediated enhancement of microRNA miR-373 impairs the JAK/STAT signaling pathway. J Virol. 2015;89:3356-3365. [PMID: 25589644 DOI: 10.1128/jvi.03085-14] [Cited by in Crossref: 69] [Cited by in F6Publishing: 71] [Article Influence: 9.9] [Reference Citation Analysis]
167 Lu YF, Goldstein DB, Urban TJ, Bradrick SS. Interferon-λ4 is a cell-autonomous type III interferon associated with pre-treatment hepatitis C virus burden. Virology 2015;476:334-40. [PMID: 25577150 DOI: 10.1016/j.virol.2014.12.020] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 4.4] [Reference Citation Analysis]
168 Henderson JA, Bilimoria D, Bubenik M, Cadilhac C, Cottrell KM, Denis F, Dietrich E, Ewing N, Falardeau G, Giroux S, L'Heureux L, Liu B, Mani N, Morris M, Nicolas O, Pereira OZ, Poisson C, Reddy TJ, Selliah S, Shawgo RS, Vaillancourt L, Wang J, Xu J, Chauret N, Berlioz-Seux F, Chan LC, Das SK, Grillot AL, Bennani YL, Maxwell JP. Synthesis and evaluation of NS5A inhibitors containing diverse heteroaromatic cores. Bioorg Med Chem Lett 2015;25:948-51. [PMID: 25577039 DOI: 10.1016/j.bmcl.2014.12.042] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
169 Aoki Y, Sugiyama M, Murata K, Yoshio S, Kurosaki M, Hashimoto S, Yatsuhashi H, Nomura H, Kang JH, Takeda T. Association of serum IFN-λ3 with inflammatory and fibrosis markers in patients with chronic hepatitis C virus infection. J Gastroenterol. 2015;50:894-902. [PMID: 25501286 DOI: 10.1007/s00535-014-1023-2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 2.9] [Reference Citation Analysis]
170 Semmo N, Weber T, Idle JR, Beyoğlu D. Metabolomics reveals that aldose reductase activity due to AKR1B10 is upregulated in hepatitis C virus infection. J Viral Hepat 2015;22:617-24. [PMID: 25487531 DOI: 10.1111/jvh.12376] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 3.3] [Reference Citation Analysis]
171 Manickam C, Reeves RK. Modeling HCV disease in animals: virology, immunology and pathogenesis of HCV and GBV-B infections. Front Microbiol. 2014;5:690. [PMID: 25538700 DOI: 10.3389/fmicb.2014.00690] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
172 Pérez-Vilaró G, Fernández-Carrillo C, Mensa L, Miquel R, Sanjuan X, Forns X, Pérez-del-Pulgar S, Díez J. Hepatitis C virus infection inhibits P-body granule formation in human livers. J Hepatol 2015;62:785-90. [PMID: 25463546 DOI: 10.1016/j.jhep.2014.11.018] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
173 Ezzikouri S, Nishimura T, Kohara M, Benjelloun S, Kino Y, Inoue K, Matsumori A, Tsukiyama-Kohara K. Inhibitory effects of Pycnogenol® on hepatitis C virus replication. Antiviral Res 2015;113:93-102. [PMID: 25446333 DOI: 10.1016/j.antiviral.2014.10.017] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
174 Cashman SB, Marsden BD, Dustin LB. The Humoral Immune Response to HCV: Understanding is Key to Vaccine Development. Front Immunol. 2014;5:550. [PMID: 25426115 DOI: 10.3389/fimmu.2014.00550] [Cited by in Crossref: 51] [Cited by in F6Publishing: 52] [Article Influence: 6.4] [Reference Citation Analysis]
175 McDonald SA, Mohamed R, Dahlui M, Naning H, Kamarulzaman A. Bridging the data gaps in the epidemiology of hepatitis C virus infection in Malaysia using multi-parameter evidence synthesis. BMC Infect Dis 2014;14:564. [PMID: 25377240 DOI: 10.1186/s12879-014-0564-6] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
176 Dubuisson J, Cosset FL. Virology and cell biology of the hepatitis C virus life cycle: an update. J Hepatol. 2014;61:S3-S13. [PMID: 25443344 DOI: 10.1016/j.jhep.2014.06.031] [Cited by in Crossref: 123] [Cited by in F6Publishing: 124] [Article Influence: 15.4] [Reference Citation Analysis]
177 Eyre NS, Helbig KJ, Beard MR. Current and future targets of antiviral therapy in the hepatitis C virus life cycle. Future Virology 2014;9:947-65. [DOI: 10.2217/fvl.14.83] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
178 Ifland L. Promoting national blood systems in developing countries: . Current Opinion in Hematology 2014;21:497-502. [DOI: 10.1097/moh.0000000000000078] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
179 Wong JA, Bhat R, Hockman D, Logan M, Chen C, Levin A, Frey SE, Belshe RB, Tyrrell DL, Law JL, Houghton M. Recombinant hepatitis C virus envelope glycoprotein vaccine elicits antibodies targeting multiple epitopes on the envelope glycoproteins associated with broad cross-neutralization. J Virol 2014;88:14278-88. [PMID: 25275133 DOI: 10.1128/JVI.01911-14] [Cited by in Crossref: 54] [Cited by in F6Publishing: 55] [Article Influence: 6.8] [Reference Citation Analysis]
180 Goto K, Kato N. MICA SNPs and the NKG2D system in virus-induced HCC. J Gastroenterol. 2015;50:261-272. [PMID: 25270965 DOI: 10.1007/s00535-014-1000-9] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 4.5] [Reference Citation Analysis]
181 Tucci F, Küppers R. Role of hepatitis C virus in B cell lymphoproliferations. Virol Sin 2014;29:3-6. [PMID: 24452541 DOI: 10.1007/s12250-014-3414-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
182 Wang L, Qiu J, Yu L, Hu X, Zhao P, Jiang Y. Increased numbers of CD5+CD19+CD1dhighIL-10+ Bregs, CD4+Foxp3+ Tregs, CD4+CXCR5+Foxp3+ follicular regulatory T (TFR) cells in CHB or CHC patients. J Transl Med 2014;12:251. [PMID: 25199644 DOI: 10.1186/s12967-014-0251-9] [Cited by in Crossref: 48] [Cited by in F6Publishing: 51] [Article Influence: 6.0] [Reference Citation Analysis]
183 Chen J, Zhao Y, Zhang C, Chen H, Feng J, Chi X, Pan Y, Du J, Guo M, Cao H, Chen H, Wang Z, Pei R, Wang Q, Pan L, Niu J, Chen X, Tang H. Persistent hepatitis C virus infections and hepatopathological manifestations in immune-competent humanized mice. Cell Res 2014;24:1050-66. [PMID: 25155355 DOI: 10.1038/cr.2014.116] [Cited by in Crossref: 54] [Cited by in F6Publishing: 53] [Article Influence: 6.8] [Reference Citation Analysis]
184 Mittal S, Sada YH, El-Serag HB, Kanwal F, Duan Z, Temple S, May SB, Kramer JR, Richardson PA, Davila JA. Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population. Clin Gastroenterol Hepatol 2015;13:594-601.e1. [PMID: 25148760 DOI: 10.1016/j.cgh.2014.08.013] [Cited by in Crossref: 164] [Cited by in F6Publishing: 176] [Article Influence: 20.5] [Reference Citation Analysis]
185 Edlin BR, Winkelstein ER. Can hepatitis C be eradicated in the United States? Antiviral Res. 2014;110:79-93. [PMID: 25110202 DOI: 10.1016/j.antiviral.2014.07.015] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 3.9] [Reference Citation Analysis]
186 Hou J, van Oord G, Groothuismink ZM, Claassen MA, Kreefft K, Zaaraoui-Boutahar F, van IJcken WF, Osterhaus AD, Janssen HL, Andeweg AC, de Knegt RJ, Boonstra A. Gene expression profiling to predict and assess the consequences of therapy-induced virus eradication in chronic hepatitis C virus infection. J Virol 2014;88:12254-64. [PMID: 25100847 DOI: 10.1128/JVI.00775-14] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
187 Barnes-seeman D, Boiselle C, Capacci-daniel C, Chopra R, Hoffmaster K, Jones CT, Kato M, Lin K, Ma S, Pan G, Shu L, Wang J, Whiteman L, Xu M, Zheng R, Fu J. Design and synthesis of lactam–thiophene carboxylic acids as potent hepatitis C virus polymerase inhibitors. Bioorganic & Medicinal Chemistry Letters 2014;24:3979-85. [DOI: 10.1016/j.bmcl.2014.06.031] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
188 Yamane D, McGivern DR, Wauthier E, Yi M, Madden VJ, Welsch C, Antes I, Wen Y, Chugh PE, McGee CE, Widman DG, Misumi I, Bandyopadhyay S, Kim S, Shimakami T, Oikawa T, Whitmire JK, Heise MT, Dittmer DP, Kao CC, Pitson SM, Merrill AH Jr, Reid LM, Lemon SM. Regulation of the hepatitis C virus RNA replicase by endogenous lipid peroxidation. Nat Med. 2014;20:927-935. [PMID: 25064127 DOI: 10.1038/nm.3610] [Cited by in Crossref: 114] [Cited by in F6Publishing: 116] [Article Influence: 14.3] [Reference Citation Analysis]
189 Dustin LB, Cashman SB, Laidlaw SM. Immune control and failure in HCV infection--tipping the balance. J Leukoc Biol. 2014;96:535-548. [PMID: 25015956 DOI: 10.1189/jlb.4ri0214-126r] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 4.1] [Reference Citation Analysis]
190 Mukaide M, Sugiyama M, Korenaga M, Murata K, Kanto T, Masaki N, Mizokami M. High-throughput and sensitive next-generation droplet digital PCR assay for the quantitation of the hepatitis C virus mutation at core amino acid 70. J Virol Methods. 2014;207:169-177. [PMID: 25019167 DOI: 10.1016/j.jviromet.2014.07.006] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
191 Atoom AM, Taylor NG, Russell RS. The elusive function of the hepatitis C virus p7 protein. Virology 2014;462-463:377-87. [PMID: 25001174 DOI: 10.1016/j.virol.2014.04.018] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 3.5] [Reference Citation Analysis]
192 El-Shamy A, Hotta H. Impact of hepatitis C virus heterogeneity on interferon sensitivity: An overview. World J Gastroenterol 2014; 20(24): 7555-7569 [PMID: 24976696 DOI: 10.3748/wjg.v20.i24.7555] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.9] [Reference Citation Analysis]
193 Vispo E, Barreiro P, Plaza Z, Fernández-Montero JV, Labarga P, de Mendoza C, Sierra-Enguita R, Treviño A, Lopez M, Soriano V. Spontaneous hepatitis C virus clearance in HIV patients with chronic hepatitis C bearing IL28B-CC alleles using antiretroviral therapy. AIDS 2014;28:1473-8. [PMID: 24637541 DOI: 10.1097/QAD.0000000000000275] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
194 Abdel-Hakeem MS, Shoukry NH. Protective immunity against hepatitis C: many shades of gray. Front Immunol. 2014;5:274. [PMID: 24982656 DOI: 10.3389/fimmu.2014.00274] [Cited by in Crossref: 60] [Cited by in F6Publishing: 69] [Article Influence: 7.5] [Reference Citation Analysis]
195 Ahlén G, Holmström F, Gibbs A, Alheim M, Frelin L. Long-term functional duration of immune responses to HCV NS3/4A induced by DNA vaccination. Gene Ther 2014;21:739-50. [PMID: 24871581 DOI: 10.1038/gt.2014.48] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
196 Chan SW. Unfolded protein response in hepatitis C virus infection. Front Microbiol. 2014;5:233. [PMID: 24904547 DOI: 10.3389/fmicb.2014.00233] [Cited by in Crossref: 23] [Cited by in F6Publishing: 39] [Article Influence: 2.9] [Reference Citation Analysis]
197 Yao W, Cai H, Li X, Li T, Hu L, Peng T. Endoplasmic reticulum stress links hepatitis C virus RNA replication to wild-type PGC-1α/liver-specific PGC-1α upregulation. J Virol 2014;88:8361-74. [PMID: 24829353 DOI: 10.1128/JVI.01202-14] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 3.4] [Reference Citation Analysis]
198 Ding K, Wang A, Boerneke MA, Dibrov SM, Hermann T. Aryl-substituted aminobenzimidazoles targeting the hepatitis C virus internal ribosome entry site. Bioorg Med Chem Lett 2014;24:3113-7. [PMID: 24856063 DOI: 10.1016/j.bmcl.2014.05.009] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
199 Carrozzo M. Hepatitis C virus: a silent killer relevant to dentistry. Oral Dis 2014;20:425-9. [PMID: 24666473 DOI: 10.1111/odi.12240] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
200 Honegger JR, Zhou Y, Walker CM. Will there be a vaccine to prevent HCV infection? Semin Liver Dis. 2014;34:79-88. [PMID: 24782261 DOI: 10.1055/s-0034-1371081] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 4.1] [Reference Citation Analysis]
201 Nikolaeva LI, Leybman EA, Sapronov GV, Yudin AN. Liver cirrhosis and hepatocellular carcinoma in patients with chronic viral hepatitis c: some epidemiologic and molecular-genetic aspects. Epidemiology and Infectious Diseases 2014;19:40-51. [DOI: 10.17816/eid40788] [Reference Citation Analysis]
202 Lee YA, Friedman SL. Reversal, maintenance or progression: what happens to the liver after a virologic cure of hepatitis C? Antiviral Res 2014;107:23-30. [PMID: 24726738 DOI: 10.1016/j.antiviral.2014.03.012] [Cited by in Crossref: 94] [Cited by in F6Publishing: 100] [Article Influence: 11.8] [Reference Citation Analysis]
203 Goody MF, Sullivan C, Kim CH. Studying the immune response to human viral infections using zebrafish. Dev Comp Immunol 2014;46:84-95. [PMID: 24718256 DOI: 10.1016/j.dci.2014.03.025] [Cited by in Crossref: 36] [Cited by in F6Publishing: 40] [Article Influence: 4.5] [Reference Citation Analysis]
204 Fauvelle C, Felmlee DJ, Baumert TF. Unraveling hepatitis C virus structure. Cell Res. 2014;24:385-386. [PMID: 24626133 DOI: 10.1038/cr.2014.31] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
205 Konreddy AK, Toyama M, Ito W, Bal C, Baba M, Sharon A. Synthesis and Anti-HCV Activity of 4-Hydroxyamino α-Pyranone Carboxamide Analogues. ACS Med Chem Lett 2014;5:259-63. [PMID: 24900815 DOI: 10.1021/ml400432f] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
206 Georgopoulou U, Dimitriadis A, Foka P, Karamichali E, Mamalaki A. Hepcidin and the iron enigma in HCV infection. Virulence. 2014;5:465-476. [PMID: 24626108 DOI: 10.4161/viru.28508] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
207 Kornberg A. Liver transplantation for hepatocellular carcinoma beyond Milan criteria: multidisciplinary approach to improve outcome. ISRN Hepatol. 2014;25:154-159. [PMID: 27335840 DOI: 10.1155/2014/706945] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
208 Eastman KJ, Yang Z, Bender JA, Mosure K, Lemm JA, Meanwell NA, Roberts SB, Knipe J, Kadow JF. Identification of a novel series of potent HCV NS5B Site I inhibitors. Bioorg Med Chem Lett 2014;24:1993-7. [PMID: 24656612 DOI: 10.1016/j.bmcl.2014.02.047] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
209 Tian Z. Outflanking HCV. Nat Immunol 2014;15:6-8. [PMID: 24352316 DOI: 10.1038/ni.2783] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
210 Chen JY, Feeney ER, Chung RT. HCV and HIV co-infection: mechanisms and management. Nat Rev Gastroenterol Hepatol. 2014;11:362-371. [PMID: 24535328 DOI: 10.1038/nrgastro.2014.17] [Cited by in Crossref: 119] [Cited by in F6Publishing: 128] [Article Influence: 14.9] [Reference Citation Analysis]
211 Barreiro P, Fernandez-Montero JV, de Mendoza C, Labarga P, Soriano V. Towards hepatitis C eradication from the HIV-infected population. Antiviral Res 2014;105:1-7. [PMID: 24534673 DOI: 10.1016/j.antiviral.2014.02.004] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
212 Rempel JD, Krueger C, Minuk GY, Wong SG. Baseline Comorbidities Enhance the Risk of Treatment-Induced Depression in HCV-Infected Men: A Pilot Study. Am J Mens Health 2014;8:427-33. [PMID: 24493076 DOI: 10.1177/1557988314521231] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
213 Bose SK, Kim H, Meyer K, Wolins N, Davidson NO, Ray R. Forkhead box transcription factor regulation and lipid accumulation by hepatitis C virus. J Virol. 2014;88:4195-4203. [PMID: 24478438 DOI: 10.1128/jvi.03327-13] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 5.4] [Reference Citation Analysis]
214 Grebely J, Dore GJ. Can hepatitis C virus infection be eradicated in people who inject drugs? Antiviral Res. 2014;104:62-72. [PMID: 24468275 DOI: 10.1016/j.antiviral.2014.01.002] [Cited by in Crossref: 79] [Cited by in F6Publishing: 84] [Article Influence: 9.9] [Reference Citation Analysis]
215 Yi M, Hu F, Joyce M, Saxena V, Welsch C, Chavez D, Guerra B, Yamane D, Veselenak R, Pyles R, Walker CM, Tyrrell L, Bourne N, Lanford RE, Lemon SM. Evolution of a cell culture-derived genotype 1a hepatitis C virus (H77S.2) during persistent infection with chronic hepatitis in a chimpanzee. J Virol 2014;88:3678-94. [PMID: 24429362 DOI: 10.1128/JVI.03540-13] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
216 Baek J, Kang S, Min H. MicroRNA-targeting therapeutics for hepatitis C. Arch Pharm Res. 2014;37:299-305. [PMID: 24385319 DOI: 10.1007/s12272-013-0318-9] [Cited by in Crossref: 30] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
217 Maekawa S, Enomoto N. Once-daily simeprevir in combination with pegylated-interferon and ribavirin: a new horizon in the era of direct-acting antiviral agent therapy for chronic hepatitis C. J Gastroenterol 2014;49:163-4. [PMID: 24356811 DOI: 10.1007/s00535-013-0926-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
218 Negro F. HCV causes systemic disorders that can be cured. Nat Rev Gastroenterol Hepatol 2014;11:77-8. [DOI: 10.1038/nrgastro.2013.222] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
219 Scheel TK, Rice CM. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat Med 2013;19:837-49. [PMID: 23836234 DOI: 10.1038/nm.3248] [Cited by in Crossref: 416] [Cited by in F6Publishing: 440] [Article Influence: 46.2] [Reference Citation Analysis]
220 Fernández-montero JV, Vispo E, Barreiro P, Mendoza C, Labarga P, Soriano V. Treatment of Hepatitis C in HIV Patients in the New Era of Direct-Acting Antivirals. Curr Hepatitis Rep 2013;12:269-75. [DOI: 10.1007/s11901-013-0179-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
221 Masrour-Roudsari J, Ebrahimpour S. Causal role of infectious agents in cancer: An overview. Caspian J Intern Med 2017;8:153-8. [PMID: 28932365 DOI: 10.22088/cjim.8.3.153] [Cited by in F6Publishing: 13] [Reference Citation Analysis]